Navigation Links
IntelliPharmaCeuitics Ltd. Announces Generic Drug Commercialization Activities
Date:10/22/2007

TORONTO, Oct. 22 /PRNewswire/ - IntelliPharmaCeutics Ltd. (the "Company") today announced the following with regard to its generic drug commercialization activities.

In late August of this year, we announced that the Company's operating affiliate IntelliPharmaCeutics Corp. ("IntelliPharmaCeutics") had received acceptance from the U.S. Food and Drug Administration for the filing of IntelliPharmaCeutics' generic drug application (known as an ANDA) for a drug product it has developed for commercialization with a drug development partner, using IntelliPharmaCeutics' proprietary controlled release drug delivery technology. The application seeks the FDA's approval to commercialize generic versions of each of 4 strengths of a branded drug called FOCALIN XR(R).

IntelliPharmaCeutics also filed the FDA's customary form of Paragraph IV certification which IntelliPharmaCeutics had delivered to the owners of certain patents listed with the FDA as pertaining to FOCALIN XR(R). This certification contains IntelliPharmaCeutics' indication that it believes that its generic versions of FOCALIN XR(R) do not infringe those patents and/or that the patents are invalid or unenforceable.

These generic drug products have been developed by IntelliPharmaCeutics under a collaboration arrangement with Par Pharmaceutical, Inc. ("Par" or "Par Pharmaceutical") which includes agreement that Par will be responsible for litigation and its costs. Par is the agent for IntelliPharmaCeutics in respect of its filing with the FDA for approval to commercialize the generic versions of FOCALIN XR(R).

Early in October, 2007, certain parties who have claimed to hold patents relating to FOCALIN XR(R) filed complaints alleging patent infringement. The complaints make such allegations against one or more of the Company, IntelliPharmaCeutics and Par. They comprise a complaint by Elan Corporation, PLC which alleges ownership of two pertinent U.S. patents and a complaint by Celgene Corporation, Norvartis Pharmaceutical and Novartis Pharma AG, which alleges ownership by Celgene of five pertinent U.S. patents. The latter complaint alleges that Novartis AG is the exclusive licensee and that Novartis Pharmaceutical is the manufacturer and distributor for FOCALIN XR(R) in the United States.

Lawsuits such as these are an ordinary and expected part of the process of obtaining approval to commercialize a generic drug product in the United States. The Company remains confident that IntelliPharmaCeutics' generic versions of FOCALIN XR(R) do not infringe those patents. Together with its development partner, Par Pharmaceutical, IntelliPharmaCeutics intends to vigorously defend against the complaints described above.


'/>"/>
SOURCE IntelliPharmaCeutics Corp.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. PM announces a new health care order for India
2. Ramdoss Announces Introduction of RCH-II
3. Britain Announces Third Transfusion Related Mad Cow Case
4. Gates Foundation Announces $287 Million In Grants Towards AIDS Vaccine
5. Tibet Announces the Dalai Lama’s Tour of South Americ
6. NHS announces further Cost cutting Measures
7. Indian PM Announces Of Setting Up India Study Center At Tashkent
8. PowderMed Announces Needle-Less Flu Vaccine
9. Malaysia Announces Prison term On People Donating HIV-Contaminated Blood
10. Australian Government Announces Survey To Tackle Childhood Obesity
11. New Zealand Announces 10-year Plan For Betterment Of Mental Health Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2017)... ... January 15, 2017 , ... San Francisco Magazine recently queried ... counties for 2017. Almost 1,000 nominations were submitted and a little over 500 ... were announced the magazine’s January 2017 issue . , Under the category ...
(Date:1/15/2017)... NJ (PRWEB) , ... January 15, 2017 , ... ... firm located in Montclair, NJ is pleased to announce that it will be ... is located in Montclair and Glen Ridge townships, servicing all surrounding towns. The ...
(Date:1/14/2017)... (PRWEB) , ... January 14, 2017 , ... AgileMinder develops ... , The Emoji Scale is now available on Apple as a fun, free ... ratings simply by choosing one of the ten color coded values on The Emoji ...
(Date:1/13/2017)... (PRWEB) , ... January 13, 2017 , ... The 18th ... Avenida America hotel on March 3-4, 2017. This Congress is expertly designed to ... the management of patients with lung cancer. , Chaired by Dr. Giorgio V. Scagliotti, ...
(Date:1/13/2017)... ... January 13, 2017 , ... With the increasing public ... of providing additional organic alternatives for customers who have grown more conscious about ... line of all-natural activated charcoal products, Moody Zook Chief Executive Officer Nate Ginsburg ...
Breaking Medicine News(10 mins):
(Date:1/16/2017)... , Jan. 16, 2017  Today, Analytics 4 Life ... devices, announced its expansion into JLABS @ ... life science incubators. As a resident in the space, ... medical device development and commercialization expertise. JLABS ... science innovation center that provides a flexible environment for ...
(Date:1/15/2017)... , January 16, 2017 Der ... Kollagenprodukten für die Regeneration des menschlichen Gewebes, gibt die ... mit sofortiger Wirkung bekannt. ... Bill Allan ... Er bekleidete eine Reihe von Geschäftsführer- und anderen Führungspositionen ...
(Date:1/13/2017)... 2017 /PRNewswire/ - InMed Pharmaceuticals, Inc. ("InMed") (CSE: IN; OTCQB: IMLFF), ... Finance and Investment Banking at Eli Lilly & Company, has ... Bott brings over 28 years of senior financial and executive ... ... has established a significant leadership position in financial and business ...
Breaking Medicine Technology: